Production (Stage)
Galmed Pharmaceuticals Ltd.
GLMD
$1.61
-$0.07-4.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.75% | -44.47% | -35.22% | -35.22% | -16.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.78% | -23.57% | -34.69% | -34.69% | -30.02% |
| Operating Income | 9.78% | 23.57% | 34.69% | 34.69% | 30.02% |
| Income Before Tax | 13.41% | -59.18% | 29.76% | 29.76% | 30.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 13.41% | -59.18% | 29.76% | 29.76% | 30.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 13.41% | -59.18% | 29.76% | 29.76% | 30.33% |
| EBIT | 9.78% | 23.57% | 34.69% | 34.69% | 30.02% |
| EBITDA | 10.68% | 23.36% | 38.35% | 38.35% | 30.19% |
| EPS Basic | 70.40% | 88.19% | 81.25% | 81.25% | 83.85% |
| Normalized Basic EPS | 70.40% | 91.23% | 81.25% | 81.25% | 85.03% |
| EPS Diluted | 70.40% | 88.19% | 81.25% | 81.25% | 83.85% |
| Normalized Diluted EPS | 70.40% | 91.23% | 81.25% | 81.25% | 85.03% |
| Average Basic Shares Outstanding | 192.52% | 1,248.15% | 274.71% | 274.71% | 331.49% |
| Average Diluted Shares Outstanding | 192.52% | 1,248.15% | 274.71% | 274.71% | 331.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |